Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis.

ABSTRACT:

Background

Sacituzumab Govitecan (SG), a first-in-class anti-trophoblast cell surface antigen-2-directed antibody-drug conjugate (ADC), has shown clinically meaningful improvement in outcomes of patients with breast cancer (BC). However, it has also been accompanied by significant toxicity. Thus, we conducted a systematic review and meta-analysis to evaluate the safety and tolerability of SG in this patient population.

Methods

We comprehensively searched PubMed, Embase, and Cochrane databases, and ASCO and ESMO websites for clinical trials (CTs) assessing the safety of SG in BC patients. All analyses were performed in R software (v.4.2.2) using random effects models. Heterogeneity was assessed using I² test.

Results

Seven studies - three randomized clinical

SUBMITTER: Dacoregio MI 

PROVIDER: S-EPMC11648803 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature